adenosine diphosphate has been researched along with Coronary Occlusion in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greyson, CR | 1 |
| Bedja, D; Borgonjon, DJ; Champion, HC; Claeys, MJ; Cos, P; Elsaesser, RS; Gabrielson, KL; Haile, A; Kaminski, PM; Kass, DA; Lazzarino, G; Moens, AL; Paolocci, N; Tavazzi, B; Timmermans, JP; Van Nassauw, L; Vrints, CJ; Wolin, MS; Wuyts, FL; Zviman, M | 1 |
2 other study(ies) available for adenosine diphosphate and Coronary Occlusion
| Article | Year |
|---|---|
Letter by Greyson regarding article, "High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury".
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cardiotonic Agents; Coronary Occlusion; Drug Evaluation, Preclinical; Endothelium, Vascular; Folic Acid; Hyperhomocysteinemia; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Premedication; Prodrugs; Purines; Rats; Rats, Wistar | 2008 |
High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cardiotonic Agents; Coronary Occlusion; Drug Evaluation, Preclinical; Endothelium, Vascular; Folic Acid; Hyperhomocysteinemia; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Premedication; Prodrugs; Purines; Rats; Rats, Wistar; Superoxides | 2008 |